Cytomed Therapeutics secures investment for subsidiary LongevityBank

CytoMed Therapeutics (GDTC) secures non-dilutive investment for its subsidiary, LongevityBank from ICH Capital. Following the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous therapies leveraging its personalized cellular banking services while parent company, CytoMed focuses on donor blood-derived allogeneic therapies which already has an approved IND Phase I clinical trial ongoing in Singapore and a Phase II Investigator-Initiated Trial in India. Allogeneic therapies have the advantage of treatment speed, accessibility and cost-effectiveness. Autologous therapies are less likely to be rejected by one’s own immune system and are better tolerated with higher acceptance level by the immune systems of patients albeit more costly than allogeneic therapies. CytoMed is pleased to announce ICH Capital has agreed to invest up to $500,000 for a 10.0% post-money stake in LongevityBank. Founded in 2001, ICH Capital is a well-known Singapore-based investment firm that provides cross-border wealth and asset management solutions for ultra-high net worth individuals and institutions across Asia-Pacific.